PDB-code
Browse PDE entries (page 8 of 31)
First 4 5 6 PreviousLast12 11 10 Next| # | Species | PDE Type | PDB | Chain | Alternate Model | Ligand | Details | File |
|---|---|---|---|---|---|---|---|---|
 | Human | PDE10 | 5c1w | B |  | |||
| Human | PDE10 | 5c28 | A | A | 6-chloro-2-cyclopropyl-5-methylpyrimidin-4-amine | | |
| Human | PDE10 | 5c28 | A | B | 6-chloro-2-cyclopropyl-5-methylpyrimidin-4-amine | | |
| Human | PDE10 | 5c28 | B | A | | ||
| Human | PDE10 | 5c28 | B | B | | ||
| Human | PDE10 | 5c29 | A | 6-chloro-2-cyclopropyl-5-methyl-N-propylpyrimidin-4-amine | | ||
| Human | PDE10 | 5c29 | B | | |||
| Human | PDE10 | 5c2a | A | 6-chloro-2-cyclopropyl-N-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-5-methylpyrimidin-4-amine | | ||
| Human | PDE10 | 5c2a | B | 6-chloro-2-cyclopropyl-N-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-5-methylpyrimidin-4-amine | | ||
| Human | PDE10 | 5c2e | A | 3-(1-hydroxy-2-methylpropan-2-yl)-5-phenyl-3,5-dihydro-1H-imidazo[4,5-c][1,8]naphthyridine-2,4-dione | | ||
| Human | PDE10 | 5c2e | B | 6-chloro-N-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-5-methyl-2-[2-(pyridin-2-yl)ethoxy]pyrimidin-4-amine | | ||
| Human | PDE10 | 5c2h | A | 3-(1-hydroxy-2-methylpropan-2-yl)-5-phenyl-3,5-dihydro-1H-imidazo[4,5-c][1,8]naphthyridine-2,4-dione | | ||
| Human | PDE10 | 5c2h | B | 6-chloro-N-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-5-methyl-2-[3-(quinolin-2-yl)propoxy]pyrimidin-4-amine | | ||
| Human | PDE10 | 5dh4 | A | A | 5-chloro-N-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine | | |
| Human | PDE10 | 5dh4 | A | B | 3-(1-hydroxy-2-methylpropan-2-yl)-5-phenyl-3,5-dihydro-1H-imidazo[4,5-c][1,8]naphthyridine-2,4-dione | | |
| Human | PDE10 | 5dh4 | B | A | 5-chloro-N-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine | | |
| Human | PDE10 | 5dh4 | B | B | 5-chloro-N-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine | | |
| Human | PDE10 | 5dh5 | A | N-[(1-methyl-1H-pyrazol-4-yl)methyl]-5-{[(1S,2S)-2-(pyridin-2-yl)cyclopropyl]methoxy}pyrazolo[1,5-a]pyrimidin-7-amine | | ||
| Human | PDE10 | 5dh5 | B | N-[(1-methyl-1H-pyrazol-4-yl)methyl]-5-{[(1S,2S)-2-(pyridin-2-yl)cyclopropyl]methoxy}pyrazolo[1,5-a]pyrimidin-7-amine | | ||
| Human | PDE10 | 5ede | A | A | 1-(4-chlorophenyl)-3-methyl-~{N}-[[(2~{R})-oxolan-2-yl]methyl]thieno[2,3-c]pyrazole-5-carboxamide | | |
| Human | PDE10 | 5ede | A | B | 1-(4-chlorophenyl)-3-methyl-~{N}-[[(2~{R})-oxolan-2-yl]methyl]thieno[2,3-c]pyrazole-5-carboxamide | | |
| Human | PDE10 | 5ede | B | A | 1-(4-chlorophenyl)-3-methyl-~{N}-[[(2~{R})-oxolan-2-yl]methyl]thieno[2,3-c]pyrazole-5-carboxamide | | |
| Human | PDE10 | 5ede | B | B | 1-(4-chlorophenyl)-3-methyl-~{N}-[[(2~{R})-oxolan-2-yl]methyl]thieno[2,3-c]pyrazole-5-carboxamide | | |
| Human | PDE10 | 5ede | C | A | 1-(4-chlorophenyl)-3-methyl-~{N}-[[(2~{R})-oxolan-2-yl]methyl]thieno[2,3-c]pyrazole-5-carboxamide | | |
| Human | PDE10 | 5ede | C | B | 1-(4-chlorophenyl)-3-methyl-~{N}-[[(2~{R})-oxolan-2-yl]methyl]thieno[2,3-c]pyrazole-5-carboxamide | | |
| Human | PDE10 | 5ede | D | A | 1-(4-chlorophenyl)-3-methyl-~{N}-[[(2~{R})-oxolan-2-yl]methyl]thieno[2,3-c]pyrazole-5-carboxamide | | |
| Human | PDE10 | 5ede | D | B | 1-(4-chlorophenyl)-3-methyl-~{N}-[[(2~{R})-oxolan-2-yl]methyl]thieno[2,3-c]pyrazole-5-carboxamide | | |
| Human | PDE10 | 5edg | A | 3-(2-chloranyl-5-phenyl-1~{H}-imidazol-4-yl)-1-[3-(trifluoromethyloxy)phenyl]pyridazin-4-one | | ||
| Human | PDE10 | 5edg | B | 3-(2-chloranyl-5-phenyl-1~{H}-imidazol-4-yl)-1-[3-(trifluoromethyloxy)phenyl]pyridazin-4-one | | ||
| Human | PDE10 | 5edg | C | 3-(2-chloranyl-5-phenyl-1~{H}-imidazol-4-yl)-1-[3-(trifluoromethyloxy)phenyl]pyridazin-4-one | |
This research was performed as part of the "Phosphodiesterase inhibitors for neglected parasitic diseases" (PDE4NPD) programme, which is supported by the European Union 7th Framework Program (FP7/2007-2013) under grant agreement n° 602666.
